â– LECTURE OVERVIEW: Kawasaki Disease is an acute, self-limiting medium-vessel necrotizing vasculitis that primarily affects infants and toddlers.
â– SPECIFIC TOXIC CHANNELS:
1. Endothelial Inflammation: Characterized by segment-like inflammation of muscular medium arteries, particularly coronary arteries.
2. Clinical Diagnoses: Requires high fever lasting over 5 days, plus at least 4 of 5 CRASH symptoms:
- C - Conjunctivitis (bilateral, non-purulent, sparing the limbus).
- R - Rash (polymorphous, erythematous).
- A - Adenopathy (cervical, unilateral, node >1.5 cm).
- S - Strawberry tongue (erythematous, with cracked red lips).
- H - Hand/foot swelling initially, with desquamation of skin under nails in recovery.
â– IMMUNOLOGICAL & CYTOKINE SIGNALLING FLUX:
Pathogen exposure or cellular distress triggers antigen-presenting cell activation. This results in the release of pro-inflammatory cytokines (such as IL-1, TNF-alpha, and IL-6) and triggers receptor-mediated cellular chemotaxis.
â– MOLECULAR PATHWAY DYNAMICS:
Intracellular cascades undergo profound modifications, altering secondary transcription levels and receptor presentation on cellular membranes.
[HY-BOARD-1076]
🌟 Dynamic Clinical Key:
Carries a high risk of developing coronary artery aneurysms in up to 25% of untreated cases. Crucially, Kawasaki disease is the only clinical condition where Aspirin (which is otherwise contraindicated in children due to Reye's syndrome) is administered, alongside intravenous immunoglobulin (IVIG). Target specific monoclonal antibodies or immune suppressors to control the hyper-inflammatory cascade. Therapeutic molecules targeting upstream signaling components demonstrate superior efficacy profiles.